Beigene Ltd (ADR)  

(Public, NASDAQ:BGNE)   Watch this stock  
Find more results for BGNE
+1.62 (1.03%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 154.95 - 158.20
52 week 34.36 - 164.15
Open 154.95
Vol / Avg. 722,346.00/394,532.00
Mkt cap 8.35B
P/E     -
Div/yield     -
EPS -2.38
Shares 696.34M
Beta     -
Inst. own 4%
Jun 1, 2018
BeiGene Ltd Annual Shareholders Meeting (Estimated) - 2:30PM EDT - Add to calendar
May 8, 2018
Q1 2018 BeiGene Ltd Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 14, 2018
BeiGene Ltd at Barclays Global Healthcare Conference - Webcast
Mar 12, 2018
BeiGene Ltd at Cowen and Company Health Care Conference
Feb 28, 2018
Q4 2017 BeiGene Ltd Earnings Release
Feb 14, 2018
BeiGene Ltd at Leerink Partners Global Healthcare Conference - Webcast
Jan 7, 2018
BeiGene Ltd Investor 1x1 Meetings at JPMorgan Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -531.74% -38.03%
Operating margin -571.13% -41.30%
EBITD margin - -39.38%
Return on average assets -36.99% -12.48%
Return on average equity -54.62% -17.69%
Employees 900 -
CDP Score - -


C/O Mourant Ozannes Corporate Services 94 Solaris Avenue, Camana Bay
Cayman Islands
+1-345-9494123 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Officers and directors

John V Oyler Chairman of the Board, Chief Executive Officer, Founder
Age: 48
Bio & Compensation  - Reuters
Howard Liang Ph.D. Chief Financial Officer and Chief Strategy Officer
Age: 52
Bio & Compensation  - Reuters
Wendy Yan Senior Vice President, Head of Regulatory Affairs
Age: 50
Bio & Compensation  - Reuters
Jason Yang M.D.Suffix is Ph.D. Senior Vice President, Head of Clinical Development
Age: 51
Bio & Compensation  - Reuters
Timothy Y. Chen Director
Age: 59
Bio & Compensation  - Reuters
Donald W. Glazer Director
Age: 71
Bio & Compensation  - Reuters
Michael J. Goller Director
Age: 40
Bio & Compensation  - Reuters
Ranjeev Krishana Director
Age: 41
Bio & Compensation  - Reuters
Xiaodong Wang Ph.D. Director
Age: 52
Bio & Compensation  - Reuters